249 related articles for article (PubMed ID: 23665339)
1. A novel tetrameric gp350 1-470 as a potential Epstein-Barr virus vaccine.
Cui X; Cao Z; Sen G; Chattopadhyay G; Fuller DH; Fuller JT; Snapper DM; Snow AL; Mond JJ; Snapper CM
Vaccine; 2013 Jun; 31(30):3039-45. PubMed ID: 23665339
[TBL] [Abstract][Full Text] [Related]
2. Rabbits immunized with Epstein-Barr virus gH/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350.
Cui X; Cao Z; Chen Q; Arjunaraja S; Snow AL; Snapper CM
Vaccine; 2016 Jul; 34(34):4050-5. PubMed ID: 27291087
[TBL] [Abstract][Full Text] [Related]
3. Immunization With Fc-Based Recombinant Epstein-Barr Virus gp350 Elicits Potent Neutralizing Humoral Immune Response in a BALB/c Mice Model.
Zhao B; Zhang X; Krummenacher C; Song S; Gao L; Zhang H; Xu M; Feng L; Feng Q; Zeng M; Xu Y; Zeng Y
Front Immunol; 2018; 9():932. PubMed ID: 29765376
[TBL] [Abstract][Full Text] [Related]
4. High Epstein-Barr Virus Load and Genomic Diversity Are Associated with Generation of gp350-Specific Neutralizing Antibodies following Acute Infectious Mononucleosis.
Weiss ER; Alter G; Ogembo JG; Henderson JL; Tabak B; Bakiş Y; Somasundaran M; Garber M; Selin L; Luzuriaga K
J Virol; 2017 Jan; 91(1):. PubMed ID: 27733645
[TBL] [Abstract][Full Text] [Related]
5. Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine.
Jackman WT; Mann KA; Hoffmann HJ; Spaete RR
Vaccine; 1999 Feb; 17(7-8):660-8. PubMed ID: 10067671
[TBL] [Abstract][Full Text] [Related]
6. A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection.
Zhang X; Zhao B; Ding M; Song S; Kang Y; Yu Y; Xu M; Xiang T; Gao L; Feng Q; Zhao Q; Zeng MS; Krummenacher C; Zeng YX
Theranostics; 2020; 10(13):5704-5718. PubMed ID: 32483413
[No Abstract] [Full Text] [Related]
7. Immunogenicity of a multiepitope plasmid DNA encoding T and B lymphocyte epitopes from latent membrane protein 2 (LMP2) of Epstein-Barr virus as a vaccine in mice.
Li W; Chen Q; Lin Q; Lv Y; Feng J; Liu J; Xu W; Chen S; Zhu X; Zhang L
Protein Pept Lett; 2013 Oct; 20(10):1136-43. PubMed ID: 23688153
[TBL] [Abstract][Full Text] [Related]
8. Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases.
Cui X; Snapper CM
Front Immunol; 2021; 12():734471. PubMed ID: 34691042
[TBL] [Abstract][Full Text] [Related]
9. Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice.
Perez EM; Foley J; Tison T; Silva R; Ogembo JG
Oncotarget; 2017 Mar; 8(12):19255-19273. PubMed ID: 27926486
[TBL] [Abstract][Full Text] [Related]
10. Recombinant Epstein-Barr virus glycoprotein 350 as a serological antigen.
Persson Berg L; Thomsson E; Hasi G; Bäckström M; Bergström T
J Virol Methods; 2020 Oct; 284():113927. PubMed ID: 32650039
[TBL] [Abstract][Full Text] [Related]
11. Peptides designed to spatially depict the Epstein-Barr virus major virion glycoprotein gp350 neutralization epitope elicit antibodies that block virus-neutralizing antibody 72A1 interaction with the native gp350 molecule.
Tanner JE; Coinçon M; Leblond V; Hu J; Fang JM; Sygusch J; Alfieri C
J Virol; 2015 May; 89(9):4932-41. PubMed ID: 25694592
[TBL] [Abstract][Full Text] [Related]
12. DNA-mediated immunization of glycoprotein 350 of Epstein-Barr virus induces the effective humoral and cellular immune responses against the antigen.
Jung S; Chung YK; Chang SH; Kim J; Kim HR; Jang HS; Lee JC; Chung GH; Jang YS
Mol Cells; 2001 Aug; 12(1):41-9. PubMed ID: 11561729
[TBL] [Abstract][Full Text] [Related]
13. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults.
Sokal EM; Hoppenbrouwers K; Vandermeulen C; Moutschen M; Léonard P; Moreels A; Haumont M; Bollen A; Smets F; Denis M
J Infect Dis; 2007 Dec; 196(12):1749-53. PubMed ID: 18190254
[TBL] [Abstract][Full Text] [Related]
14. Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells.
Bu W; Joyce MG; Nguyen H; Banh DV; Aguilar F; Tariq Z; Yap ML; Tsujimura Y; Gillespie RA; Tsybovsky Y; Andrews SF; Narpala SR; McDermott AB; Rossmann MG; Yasutomi Y; Nabel GJ; Kanekiyo M; Cohen JI
Immunity; 2019 May; 50(5):1305-1316.e6. PubMed ID: 30979688
[TBL] [Abstract][Full Text] [Related]
15. Identification of multiple potent neutralizing and non-neutralizing antibodies against Epstein-Barr virus gp350 protein with potential for clinical application and as reagents for mapping immunodominant epitopes.
Mutsvunguma LZ; Rodriguez E; Escalante GM; Muniraju M; Williams JC; Warden C; Qin H; Wang J; Wu X; Barasa A; Mulama DH; Mwangi W; Ogembo JG
Virology; 2019 Oct; 536():1-15. PubMed ID: 31377598
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus gp350-specific antibody titers and antibody-dependent cellular cytotoxic effector function in different groups of patients: a study using cloned gp350-expressing transfected human T cell targets.
Khyatti M; Stefanescu I; Blagdon M; Menezes J
J Infect Dis; 1994 Dec; 170(6):1439-47. PubMed ID: 7995983
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus (EBV) hyperimmune globulin isolated from donors with high gp350 antibody titers protect humanized mice from challenge with EBV.
Kim J; Bu W; Mine S; Tariq Z; Nguyen H; Wang Y; Tolman C; Mond J; Cohen JI
Virology; 2021 Sep; 561():80-86. PubMed ID: 34171765
[TBL] [Abstract][Full Text] [Related]
18. Identification of the critical attribute(s) of EBV gp350 antigen required for elicitation of a neutralizing antibody response in vivo.
Servat E; Ro BW; Cayatte C; Gemmell L; Barton C; Rao E; Lin R; Zuo F; Woo JC; Hayes GM
Vaccine; 2015 Nov; 33(48):6771-7. PubMed ID: 26485517
[TBL] [Abstract][Full Text] [Related]
19. Immunization with a Self-Assembled Nanoparticle Vaccine Elicits Potent Neutralizing Antibody Responses against EBV Infection.
Kang YF; Zhang X; Yu XH; Zheng Q; Liu Z; Li JP; Sun C; Kong XW; Zhu QY; Chen HW; Huang Y; Xu M; Zhong Q; Zeng YX; Zeng MS
Nano Lett; 2021 Mar; 21(6):2476-2486. PubMed ID: 33683126
[TBL] [Abstract][Full Text] [Related]
20. High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma.
Coghill AE; Bu W; Nguyen H; Hsu WL; Yu KJ; Lou PJ; Wang CP; Chen CJ; Hildesheim A; Cohen JI
Clin Cancer Res; 2016 Jul; 22(14):3451-7. PubMed ID: 26920891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
